Fractyl Health logo
Fractyl Health
GUTS | NASDAQ
Chart Builder DCF Calculator
$0.99
+$0.09 (+9.56%)
At close: Nov 16, 2026, 4:00 PM ET
$0.97
-$0.02 (-1.54%)
After-hours: Nov 16, 2026, 7:30 PM ET

Fractyl Health Company Profile

Company profile explained

Company Profile

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans. It develops Rejuva, a novel adeno-associated virus delivered pancreatic gene therapy platform that is designed to enable long-term remission of T2D and obesity by durably altering metabolic hormone function in the pancreatic islet cells of patients. Fractyl Health, Inc. was formerly known as Fractyl Laboratories Inc. and changed its name to Fractyl Health, Inc. on June 09, 2021. The company was incorporated in 2010 and is headquartered in Burlington, Massachusetts.

Key Executives

Name Position
Harith Rajagopalan Co-Founder, CEO, Director & Principal Executive Officer
Lara Smith Weber Chief Financial Officer & Treasurer
Brian Luque Head of Investor Relations & Corporate Development
Jay D. Caplan BSEE Co-Founder, Chief Product Officer & President
Jon Fitzgerald Senior Vice President of Regulatory, Quality & Clinical
Mike Zumdahl Senior Vice President of Market Access & Commercial Strategy
Sarah S. Toomey General Counsel & Corporate Secretary

Latest SEC Filings

Date Type Title
Oct 22, 2026 8-K Current Report
Oct 16, 2026 8-K Current Report
Oct 13, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 01, 2026 8-K Current Report
Sep 24, 2026 8-K Current Report
Sep 16, 2026 4 Filing
Sep 11, 2026 8-K Current Report
Aug 24, 2026 DEF 14A Filing
Aug 14, 2026 PRE 14A Filing
Aug 10, 2026 10-Q Quarterly Report
View All SEC Filings ➞
Fractyl Health
Fractyl Health logo
Country United States
IPO Date Feb 2, 2024
Industry Biotechnology
Sector Healthcare
Employees 100
CEO Harith Rajagopalan

Contact Details

3 Van de Graaff Drive Burlington, Massachusetts 01803 United States

Stock Details

Ticker Symbol GUTS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001572616
CUSIP Number 35168W202
ISIN Number US35168W2026
SIC Code 3841

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.